A Phase 3, Multi-center, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Moderate to Severe Forehead Lines in China
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles; Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 16 Apr 2024 Planned End Date changed from 7 Dec 2024 to 18 Sep 2024.
- 16 Apr 2024 Planned primary completion date changed from 7 Dec 2024 to 18 Sep 2024.